Evidencia del uso de antidepresivos en Fibromialgia (fm)
PDF

Palabras clave

Fibromialgia
Comorbilidad
Antidepresivos Fibromyalgia
Comorbidity
Antidepressants

Cómo citar

Millán , A., & Rojas, M. I. (2010). Evidencia del uso de antidepresivos en Fibromialgia (fm). Revista Médica Sanitas, 13(2), 20-26. Recuperado a partir de //revistas.unisanitas.edu.co/index.php/rms/article/view/252

Resumen

Introducción: el avance en el entendimiento de la fibromialgia, como una patología de etiología multifactorial, con componentes biológicos, psicológicos y sociales, en la cual se encuentra con frecuencia comorbilidad psiquiátrica justifica evaluar la eficacia y seguridad del tratamiento especialmente de los antidepresivos. Método: búsqueda en la literatura biomédica en Medline, OVID, Proquest, Scielo y EMBASE, cruzando la expresión MeSH fibromialgya con pathophysiology y clinical trial, delimitando los resultados a los estudios clínicos, revisiones sistemáticas y/o metanálisis en español o inglés en los últimos 25 años en la población adulta. Resultados: se seleccionaron los artículos arrojados por nuestra búsqueda, considerados de relevancia clínica por la calidad metodológica y los resultados en términos de seguridad, eficacia y efectividad. Conclusiones: la FM es una enfermedad generalizada, incapacitante, de etiología multifactorial en donde los factores psicosociales y las comorbilidades psiquiátricas son parte fundamental en el desarrollo y mantenimiento de la misma. La combinación del tratamiento farmacológico y no farmacológico sigue siendo la recomendación más importante en los pacientes con FM. Los antidepresivos son una opción útil y segura en el tratamiento de la FM especialmente los antidepresivos triciclicos y los antidepresivos duales como la duloxetina y el milnacipran.

PDF

Citas

Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia - a review. Joint Bone Spine 2008 May;75(3):273-9. https://doi.org/10.1016/j.jbspin.2007.09.010

Yunus MB. A comprehensive medical evaluation of patients with fibromyalgia syndrome. Rheum Dis Clin North Am 2002 May;28(2):201-vi. https://doi.org/10.1016/S0889-857X(01)00002-3

Bruckle W, Zeidler H. [Fibromyalgia]. Internist (Berl) 2004 Aug;45(8):923-32. https://doi.org/10.1007/s00108-004-1224-5

Biewer W, Conrad I, Hauser W. [Fibromyalgia]. Schmerz 2004 Apr;18(2):118-24. https://doi.org/10.1007/s00482-003-0300-4

Melillo N, Corrado A, Quarta L, D'Onofrio F, Trotta A, Cantatore FP. [Fibromyalgic syndrome: new perspectives in rehabilitation and management. A review]. Minerva Med 2005 Dec;96(6):417-23.

Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005 Aug;75: 6-21.

Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990 Feb;33(2):160-72.

Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM. Clinical characteristics of fibrositis. I. A "blinded," controlled study of symptoms and tender points. Arthritis Rheum 1983 Jul;26(7): 817-24. https://doi.org/10.1002/art.1780260701

Yunus MB. Diagnosis, etiology, and management of fibromyalgia syndrome: an update. Compr Ther 1988 Apr;14(4):8-20.

Greenfield S, Fitzcharles MA, Esdaile JM. Reactive fibromyalgia syndrome. Arthritis Rheum 1992 Jun;35(6):678-81. https://doi.org/10.1002/art.1780350612

Raphael KG, Janal MN, Nayak S. Comorbidity of fibromyalgia and posttraumatic stress disorder symptoms in a community sample of women. Pain Med 2004 Mar;5(1):33-41. https://doi.org/10.1111/j.1526-4637.2004.04003.x

Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999 Dec;94(12):3541-6. https://doi.org/10.1111/j.1572-0241.1999.01643.x

Smythe HA, Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bull Rheum Dis 1977;28(1):928-31.

Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am 1989 Feb;15(1):1-18.

Yunus MB. Psychological aspects of fibromyalgia syndrome: a component of the dysfunctional spectrum syndrome. Baillieres Clin Rheumatol 1994 Nov;8(4):811-37. https://doi.org/10.1016/S0950-3579(05)80050-0

Turk DC, Okifuji A, Sinclair JD, Starz TW. Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol 1996 Jul;23(7):1255-62.

Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007 Jan;8(1):67-74. https://doi.org/10.2217/14622416.8.1.67

Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, et al. Family study of fibromyalgia. Arthritis Rheum 2004 Mar;50(3):944-52. https://doi.org/10.1002/art.20042

Burda CD, Cox FR, Osborne P. Histocompatability antigens in the fibrositis (fibromyalgia) syndrome. Clin Exp Rheumatol 1986 Oct;4(4):355-8.

Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999 Feb;26(2):408-12.

Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxietyrelated personality traits. Arthritis Rheum 2002 Mar;46(3):845-7. https://doi.org/10.1002/art.10103

Wood PB, Patterson JC, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007 Jan;8(1):51-8. https://doi.org/10.1016/j.jpain.2006.05.014

Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 2003 Jun;75(1):77-82. https://doi.org/10.1016/S0165-0327(02)00025-3

Treister R, Pud D, Ebstein RP, Laiba E, Gershon E, Haddad M, et al. Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans. Pain 2009 Dec 15;147(1-3):187-93. https://doi.org/10.1016/j.pain.2009.09.001

Walker EA, Keegan D, Gardner G, Sullivan M, Katon WJ, Bernstein D. Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability. Psychosom Med 1997 Nov;59(6):565-71. https://doi.org/10.1097/00006842-199711000-00002

Amital D, Fostick L, Polliack ML, Segev S, Zohar J, Rubinow A, et al. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities? J Psychosom Res 2006 Nov;61(5):663-9. https://doi.org/10.1016/j.jpsychores.2006.07.003

Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007 May 15;146(10):726-34. https://doi.org/10.7326/0003-4819-146-10-200705150-00006

Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann KT, Gren LH, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006 Jun;12(3):124-8. https://doi.org/10.1097/01.rhu.0000221817.46231.18

Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Psychiatric comorbidities in a community sample of women with fibromyalgia. Pain 2006 Sep;124(1-2):117-25. https://doi.org/10.1016/j.pain.2006.04.004

Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004 Nov 17;292(19):2388-95. https://doi.org/10.1001/jama.292.19.2388

Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009 Jan 14; 301(2):198-209. https://doi.org/10.1001/jama.2008.944

Acuna C. Duloxetine for the treatment of fibromyalgia. Drugs Today (Barc ) 2008 Oct;44(10): 725-34. https://doi.org/10.1358/dot.2008.44.10.1269675

Owen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc ) 2008 Sep;44(9): 653-60. https://doi.org/10.1358/dot.2008.44.9.1256003

Pae CU, Marks DM, Shah M, Han C, Ham BJ, Patkar AA, et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol 2009 Nov;32(6):355-63. https://doi.org/10.1097/WNF.0b013e3181ac155b

Dryson E. Venlafaxine and fibromyalgia. N Z Med J 2000 Mar 10;113(1105):87. https://doi.org/10.1023/A:1008387132377

Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003 Nov;37(11):1561-5. https://doi.org/10.1345/aph.1D112

Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995 Sep;38(9):1211-7. https://doi.org/10.1002/art.1780380906

Arnold LM, Keck PE, Jr., Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000 Mar;41(2):104-13. https://doi.org/10.1176/appi.psy.41.2.104

Dwight MM, Arnold LM, O'Brien H, Metzger R, MorrisPark E, Keck PE, Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998 Jan;39(1):14-7. https://doi.org/10.1016/S0033-3182(98)71375-1

Ablin JN, Buskila D. Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs 2008 Mar; 13(1):53-62. https://doi.org/10.1517/14728214.13.1.53

Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol 2007 Mar;19(2):111-7.

Dobkin PL, Sita A, Sewitch MJ. Predictors of adherence to treatment in women with fibromyalgia. Clin J Pain 2006 Mar;22(3):286-94. https://doi.org/10.1097/01.ajp.0000173016.87612.4b

Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Medication adherence in patients with chronic non-malignant pain: is there a problem? Eur J Pain 2009 Feb;13(2):115-23. https://doi.org/10.1016/j.ejpain.2008.02.010

Duncan B, White A, Rahman A. Acupuncture in the treatment of fibromyalgia in tertiary care--a case series. Acupunct Med 2007 Dec;25(4):137-47. https://doi.org/10.1136/aim.25.4.137

Valim V, Oliveira L, Suda A, Silva L, de AM, Barros NT, et al. Aerobic fitness effects in fibromyalgia. J Rheumatol 2003 May;30(5):1060-9.

Bradley LA. Cognitive-behavioral therapy for primary fibromyalgia. J Rheumatol Suppl 1989 Nov;19:131-6.

Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol 2006 Aug;2(8):416-24. https://doi.org/10.1038/ncprheum0245

Busch AJ, Schachter CL, Overend TJ, Peloso PM, Barber KA. Exercise for fibromyalgia: a systematic review. J Rheumatol 2008 Jun;35(6):1130-44.

Burckhardt CS. Nonpharmacologic management strategies in fibromyalgia. Rheum Dis Clin North Am 2002 May;28(2):291-304. https://doi.org/10.1016/S0889-857X(01)00005-9

Casale R, Cazzola M, Arioli G, Gracely RH, Ceccherelli F, Atzeni F, et al. Non pharmacological treatments in fibromyalgia. Reumatismo 2008 Jul;60 Suppl 1:59-69.

Jackel WH, Genth E. [Fibromyalgia]. Z Rheumatol 2007 Nov;66(7):579-90. https://doi.org/10.1007/s00393-007-0229-6

Descargas

Los datos de descargas todavía no están disponibles.